H.C. Wainwright assumed coverage of Xeris Biopharma (XERS) with a Buy rating and $10 price target The firm believes the commercial potential of the company’s commercial portfolio remains “meaningfully underappreciated.” The portfolio has the potential to drive further Xeris stock appreciation, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS: